IMIDAZO[1',2':1,6]PYRIDO[2,3-D]PYRIMIDINE COMPOUND AS PROTEIN KINASE INHIBITOR
申请人:SHENGKE PHARMACEUTICALS (JIANGSU) LTD.
公开号:US20200270251A1
公开(公告)日:2020-08-27
Provided is an imidazo[1′;2′:1,6]pyrido[2,3-d]pyrimidine compound of general formula (I). The compound can be used in treating a cell proliferative disorder and is a cyclin-dependent kinase (CDK) inhibitor with broad-spectrum and strong activity.
1H-IMIDAZO[4,5-H]QUINAZOLINE COMPOUND AS PROTEIN KINASE INHIBITOR
申请人:Shengke Pharmaceuticals (Jiangsu) Ltd.
公开号:EP3608321A1
公开(公告)日:2020-02-12
Provided is a 1H-imidazo[4,5-h]quinazoline compound of formula (I). The compound is a broad spectrum inhibitor having strong activity for cyclin-dependent kinase (CDK) and is applicable in treating cell proliferative disorder
Imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound as protein kinase inhibitor
申请人:SHENGKE PHARMACEUTICALS (JIANGSU) LTD.
公开号:US11091485B2
公开(公告)日:2021-08-17
Provided is an imidazo[1′,2′:1,6]pyrido[2,3-d]pyrimidine compound of general formula (I). The compound can be used in treating a cell proliferative disorder and is a cyclin-dependent kinase (CDK) inhibitor with broad-spectrum and strong activity.
Substituted pyrazolo[4,3-H]quinazolines as protein kinase inhibitors
申请人:SHENGKE PHARMACEUTICALS (JIANGSU) LTD.
公开号:US11319323B2
公开(公告)日:2022-05-03
A 1H-pyrazolo[4,3-H]quinazoline compound represented by formula (I) can be used for treating cell proliferation dysfunction, and is an broad-spectrum and strongly-active inhibitor for a cell cyclin-dependent kinase (CDK).
1H-PYRAZOLO[4,3-H]QUINAZOLINE COMPOUND SERVING AS PROTEIN KINASE INHIBITOR
申请人:SHENGKE PHARMACEUTICALS (JIANGSU) LTD.
公开号:US20210147424A1
公开(公告)日:2021-05-20
A 1H-pyrazolo[4,3-H]quinazoline compound represented by formula (I) can be used for treating cell proliferation dysfunction, and is an broad-spectrum and strongly-active inhibitor for a cell cyclin-dependent kinase (CDK).